Privium Fund Management B.V. Has $804,000 Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Privium Fund Management B.V. raised its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 52.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 119,000 shares of the company’s stock after buying an additional 41,000 shares during the period. Privium Fund Management B.V.’s holdings in Recursion Pharmaceuticals were worth $804,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Farther Finance Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock valued at $52,000 after purchasing an additional 1,353 shares during the period. Wedmont Private Capital boosted its holdings in shares of Recursion Pharmaceuticals by 10.6% during the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after buying an additional 2,000 shares during the period. Daiwa Securities Group Inc. grew its stake in Recursion Pharmaceuticals by 28.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company’s stock valued at $69,000 after buying an additional 2,235 shares during the last quarter. Green Alpha Advisors LLC raised its holdings in Recursion Pharmaceuticals by 3.6% in the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company’s stock valued at $454,000 after acquiring an additional 2,346 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Recursion Pharmaceuticals by 5.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 52,530 shares of the company’s stock worth $346,000 after acquiring an additional 2,667 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $6.39 on Wednesday. The firm has a market cap of $2.57 billion, a P/E ratio of -4.18 and a beta of 0.85. The business’s fifty day moving average is $7.50 and its 200-day moving average is $7.01. Recursion Pharmaceuticals, Inc. has a 52-week low of $5.60 and a 52-week high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s quarterly revenue was down 57.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.42) earnings per share. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Finally, Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.